Skip to main content

Table 1 Summary and comparison of the South African adult ART guidelines

From: Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa

 

2004

2010

2012/2013

2015

Eligible to start

CD4 ≤ 200 cells/mm3

WHO stage IV

CD4 count ≤ 200 cells/mm3

WHO stage IV, MDR or XDR

TB if CD4 ≤ 350 cells/mm3

Pregnant women with CD4 ≤ 350 cells/mm3 or WHO stage III/IV

CD4 count ≤ 350 cells/mm3

WHO stage III or IV

TB

Pregnant or breastfeeding, irrespective of CD4

CD4 count ≤ 500 cells/mm3

Active TB disease, HIV positive and pregnant or breastfeeding, known HBV co-infection irrespective of CD4 count or clinical stage

WHO stage III or IV irrespective of CD4 count

First-line ART regimen

d4t + 3TC + EFV

d4t + 3TC + NVP

TDF + 3TC/FTC + EFV/NVP

d4t + 3TC + EFV/NPV

AZT + 3TC + EFV/NVP

TDF + 3TC/FTC + EFV/NVP

AZT + 3TC + EFV/NVP

d4t + 3TC + EFV/NVP

ABC + 3TC + EFV/NVP

TDF + 3TC/FTC + EFV

TDF + 3TC/FTC + NVP/LPV/r

ABC + 3TC + EFV/NVP

Failing first-line

No resistance testing for first-line failure

Second-line ART regimen

AZT/ddI/LPV/r

TDF + 3TC/FTC + LPV/r

AZT + 3TC + LPV/r

AZT + 3TC + LPV/r

TDF + 3TC/FTC + LPV/r

Switch LPV/r to ATV/r with dyslipidaemia

AZT + 3TC + LPV/r

AZT + TDF + 3TC + LPV/r [if Hep B co-infected)

TDF + 3TC/FTC + LPV/r

Switch LPV/r to ATV/r with dyslipidaemia

Failing second-line/third-line ART

 

Specialist referral

Specialist referral for regimen with raltegravir/darunavir/etravirine

Documented PI resistance

Refer to expert committee for possible darunavir-ritonavir,

raltegravir, etravirine or some combination

Monitoring

CD4 and VL at baseline and 6 monthly

ALT for patients on NVP at baseline, 2, 4 and 8 weeks and 6 monthly thereafter

FBC at baseline, monthly for 3 month and then 6 monthly

Fasting cholesterol and triglycerides at baseline, 6 month and every 12 month thereafter

Fasting glucose at baseline and 12 month

Serum creatinine at baseline if starting on TDF

ALT at baseline and if symptomatic on NVP

CD4 and VL at month 6, 1 year and every 12 month thereafter

FBC or haemoglobin at baseline and month 1, 2, 3 and 6 if on AZT

Creatinine at month 3 and 6 and every 12 month if on TDF

Fasting cholesterol and triglycerides at 3 month if on LPV/r

Serum creatinine at baseline if starting on TDF

ALT at baseline and if symptomatic on NVP

CD4 at 1 year on ART

VL at month 6, 1 year on ART and every 12 month

FBC or haemoglobin at baseline and month 3 and 6 if on AZT

Creatinine at month 3, 6, 1 year on ART and every 12 months if on TDF

Fasting cholesterol and triglycerides at month 3 if on LPV/r

Serum creatinine at baseline if starting on TDF

ALT at baseline and if symptomatic on NVP

CD4 at 1 year on ART—once a CD4 reaches 200 cells/mm3 no further annual CD4 monitoring

VL at month 6, 1 year on ART and every 12 month

FBC or haemoglobin at baseline and month 3 and 6 if on AZT

Creatinine at month 3, 6, 1 year on ART and every 12 months if

on TDF Fasting cholesterol and triglycerides at start

and month 3 if on LPV/r